Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01, R21)
Funding Agency: National Institutes of Health
This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).
This FOA runs in parallel with an FOA of identical scientific scope, PA-19-111, which utilizes the Exploratory/Developmental Grant (R21) mechanism to support investigation of novel scientific ideas or new model systems, tools or technologies that have the potential for significant impact on biomedical or biobehavioral research.
- R01 Due Dates: Feb. 5, Jun. 5, Oct. 5
- R21 Due Dates: Feb. 16, Jun. 16, Oct. 16
For more Information: https://grants.nih.gov/grants/guide/pa-files/PA-19-112.html